JLE

Hépato-Gastro & Oncologie Digestive

MENU

Anti-TNF in IBD on mono- or combotherapy: when to stop or reduce the dose? Volume 30, issue 4, April 2023

Authors
CHU de Saint-Étienne, Service d’hépato-gastro-entérologie, Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez
* Correspondance : X. Roblin

Discontinuation of one of the infliximab-immunosuppressant combination ­therapy in patients in prolonged remission of Crohn’s disease is marked by ­symptomatic relapse when infliximab is discontinued but not when the immunosuppressant is discontinued. In patients in long-term remission on adalimumab, extending the frequency of injections is associated with a risk of relapse in one quarter of cases. These data suggest caution before considering de-escalation in patients who volunteer for prolonged remission.